ICML 2019 | Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the use of venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL). This was taken from the clinical data of 4 patients at his center, indicating that treatment with venetoclax is feasible and effective in patients with CLL and relapsed disease after alloHCT. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Get great new content delivered to your inboxSign up